XENICAL Drug Patent Profile

When do Xenical patents expire, and what generic alternatives are available?

Xenical is a drug marketed by Cheplapharm and is included in one NDA.

The generic ingredient in XENICAL is orlistat. There are twelve drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the orlistat profile page.

Summary for XENICAL

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	103
Clinical Trials:	22
Drug Prices:	Drug price information for XENICAL
What excipients (inactive ingredients) are in XENICAL?	XENICAL excipients list
DailyMed Link:	XENICAL at DailyMed

See drug prices for XENICAL

Recent Clinical Trials for XENICAL

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Universidad Católica San Antonio de Murcia	PHASE1
October 6 University	NA
Pharos University in Alexandria	NA

See all XENICAL clinical trials

Pharmacology for XENICAL

Drug Class	Intestinal Lipase Inhibitor
Mechanism of Action	Lipase Inhibitors

US Patents and Regulatory Information for XENICAL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Cheplapharm	XENICAL	orlistat	CAPSULE;ORAL	020766-001	Apr 23, 1999		RX	Yes	Yes

EU/EMA Drug Approvals for XENICAL

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
GlaxoSmithKline (Ireland) Limited	Alli (previously Orlistat GSK)	orlistat	EMEA/H/C/000854Alli is indicated for weight loss in adults who are overweight (body mass index, BMI, ≥ 28 kg/m2) and should be taken in conjunction with a mildly hypocaloric, lower-fat diet.	Authorised	no	no	no	2007-07-22
CHEPLAPHARM Arzneimittel GmbH	Xenical	orlistat	EMEA/H/C/000154Xenical is indicated in conjunction with a mildly hypocaloric diet for the treatment of obese patients with a body mass index (BMI) greater or equal to 30 kg/m2, or overweight patients (BMI > 28 kg/m2) with associated risk factors.Treatment with orlistat should be discontinued after 12 weeks if patients have been unable to lose at least 5% of the body weight as measured at the start of therapy.	Authorised	no	no	no	1998-07-29

International Patents for XENICAL

See the table below for patents covering XENICAL around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	200027
Latvia	5747	Heksadekanskabes un heksadekadienskabes atvasinajumi
Australia	572851
Hong Kong	1021313
World Intellectual Property Organization (WIPO)	9834607
Czech Republic	9803528
Malaysia	118371	TETRAHYDROLIPSTATIN CONTAINING COMPOSITIONS

Supplementary Protection Certificates for XENICAL

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0129748	98C0042	Belgium		PRODUCT NAME: ORLISTAT; REGISTRATION NO/DATE: EU/1/98/071/001 19980729
0129748	SPC/GB98/044	United Kingdom		PRODUCT NAME: ORLISTAT; REGISTERED: UK EU/1/98/071/001 19980729; UK EU/1/98/071/002 19980729; UK EU/1/98/071/003 19980729; UK EO/1/98/071/004 19980729; UK EU/1/98/071/005 19980729; UK EU/1/98/071/006 19980729

Market Overview and Financial Trajectory for Xenical

Last updated: February 14, 2026

Xenical (orlistat), developed by Roche, is a weight-loss medication approved by the FDA in 1999. Its primary indication is obesity management and weight reduction in conjunction with a reduced-calorie diet. The drug operates by inhibiting gastrointestinal lipases, decreasing fat absorption by roughly 30%.

---

Market Size and Trends

The global obesity drug market, which includes Xenical, is forecasted to reach $19.4 billion by 2027, growing at a CAGR of approximately 15% from 2022 (Fortune Business Insights). Xenical holds a significant share due to early market entry and established FDA approval, but competition from newer agents influences its market dynamics.

---

Key Competitors and Market Position

Xenical's main competitors include:

• Qsymia (phentermine-topiramate): Approved in 2012; faster onset, weight loss efficacy, but side effect profile varies.
• Contrave (naltrexone-bupropion): Approved in 2014; appetite suppression.
• Saxenda (liraglutide): Approved in 2014; injectable, higher efficacy but more costly.
• Alli (orlistat OTC): Approved in 2007; lower dose, accessible over-the-counter.

Despite competition, Xenical maintains a niche owing to its established safety profile and longstanding approval status.

---

Regulatory and Patent Landscape

Xenical's patent in the U.S. expired in 2018, opening the market to generic formulations, which reduces pricing power and profit margins. Roche's strategic focus shifted toward newer obesity treatments and combination therapies.

In markets outside the U.S., patent protections may last longer, offering period of patent exclusivity, impacting regional revenues.

---

Revenue Trends and Financial Performance

Historical data outlines a decline in Xenical's global sales post-2018 due to patent expiration, increased generic competition, and availability of OTC alternatives. Roche's 2021 annual report indicates:

Year	Estimated Global Sales	Notes
2015	$500 million	Peak sales
2018	$300 million	Patent expiry, entry of generics
2021	$150 million	Continuing decline, generic share rising

The decline is consistent with industry trends affecting branded obesity drugs.

---

Strategic Factors Influencing Financial Trajectory

• Market Penetration: Retail expansion in emerging markets offers growth opportunities.
• Pricing Pressure: Generics reduce affordability, affecting profit margins.
• Regulatory Developments: Approval of new, more effective agents like semaglutide-based therapies shifts market share.
• Pipeline and Formulation Innovation: Roche’s possible development of combination therapies or new delivery mechanisms could influence future sales.

---

Future Outlook and Potential Growth Drivers

Xenical's future depends on several factors:

• Generic Competition: Will continue to suppress revenues unless Roche introduces reformulations or combination therapies.
• Emerging Markets: High obesity prevalence presents growth prospects if affordability barriers are addressed.
• Pharmacoeconomic Shift: Insurers' reimbursement policies favor newer agents with superior efficacy, limiting Xenical's market share.

Current indications suggest a plateauing or declining revenue trajectory unless Roche adopts strategic repositioning or develops next-generation formulations.

---

Key Takeaways

• Xenical remains a marketed obesity drug with a long history since FDA approval in 1999.
• The product's revenue peaked around 2015, with steep declines following patent expiration in 2018.
• Generic formulations have eroded its market share, compounded by newer, more efficacious obesity therapies.
• Revenue prospects hinge on regional growth, competitive dynamics, and Roche’s innovation strategies.
• The global obesity market's expansion presents opportunities, but competitive pressure is high.

---

Frequently Asked Questions

1. How does Xenical compare to newer obesity medications in efficacy?
Newer agents like semaglutide (Wegovy) demonstrate higher weight loss percentages (up to 15%) versus Xenical’s typical 5-10%, influencing prescriber preferences.

2. What impact does patent expiry have on Xenical’s sales?
Patent expiry in 2018 allowed generics to enter the market, significantly reducing brand sales and profit margins.

3. Are there ongoing development efforts for Xenical or similar drugs?
Roche and competitors invest in next-generation formulations and combination therapies, but specific developments for Xenical are limited.

4. How do regional regulations affect Xenical’s market?
Patent protections vary globally; in regions like Europe and Asia, longer regulatory exclusivity can sustain sales temporarily.

5. Will Xenical regain market share with new formulations?
Unlikely, given competition from efficacious injectable agents; focus appears shifted toward newer obesity pharmacotherapies.

---

References

1. Fortune Business Insights. "Obesity Drugs Market Size, Share & Industry Analysis, 2022-2027."
2. Roche Annual Reports. 2015-2021.
3. U.S. FDA Label for Xenical.
4. GlobalData. "Obesity Pharmacotherapy Market Forecast."